Stay updated on Short Course Daratumumab in Patients With Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Short Course Daratumumab in Patients With Multiple Myeloma Clinical Trial page.

Latest updates to the Short Course Daratumumab in Patients With Multiple Myeloma Clinical Trial page
- Check3 days agoChange DetectedA MedlinePlus Genetics resource about multiple myeloma is listed among the study’s related topics, and the site revision identifier changes from v3.8.0 to v3.8.1.SummaryDifference0.2%

- Check10 days agoChange DetectedThe clinical-trial record for the completed short-course daratumumab study is displayed, with details on its design, participant criteria, sites, and study measures. A study protocol and statistical analysis plan are also listed.SummaryDifference50%

- Check17 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check31 days agoChange DetectedA site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the error page. The displayed site revision changes from v3.7.0 to v3.7.2.SummaryDifference1%

- Check59 days agoChange DetectedThe study page for NCT03490344 now presents a 403 Forbidden error, making the page inaccessible; the 403 page replaces the usual study details and navigation.SummaryDifference18%

- Check66 days agoChange DetectedRevision indicator on the page now shows Revision: v3.7.0, replacing v3.6.6, signaling a platform update rather than changes to study content.SummaryDifference0.1%

Stay in the know with updates to Short Course Daratumumab in Patients With Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Short Course Daratumumab in Patients With Multiple Myeloma Clinical Trial page.